These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22044409)

  • 1. Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients.
    Zhu H; Ge W
    Pharmacogenomics; 2011 Nov; 12(11):1505-8. PubMed ID: 22044409
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
    de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
    Clin Pharmacol Ther; 2011 Sep; 90(3):414-22. PubMed ID: 21753749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.
    Pilmore H;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S88-97. PubMed ID: 17316287
    [No Abstract]   [Full Text] [Related]  

  • 4. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CARI guidelines. Calcineurin inhibitors in paediatric renal transplantation.
    McTaggart S;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S106-10. PubMed ID: 17316270
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of the unfolded protein response by calcineurin inhibitors: a double-edged sword in renal transplantation.
    Kitamura M
    Nephrol Dial Transplant; 2010 Jan; 25(1):6-9. PubMed ID: 19797334
    [No Abstract]   [Full Text] [Related]  

  • 8. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
    Martínez-Castelao A; Sarrias X; Bestard O; Gil-Vernet S; Serón D; Cruzado JM; Moreso F; Díez-Noguera A; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3788-90. PubMed ID: 16386539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
    Koefoed-Nielsen PB; Karamperis N; Jørgensen KA
    Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunosuppressive therapy without calcineurin inhibitors for renal transplants? Perhaps we should be cautions...].
    Fasoli G
    G Ital Nefrol; 2007; 24(2):110. PubMed ID: 17458825
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M; Romano-Moreno S; García-Hernández M; Chevaile-Ramos JA; Layseca-Espinosa E; González-Amaro R; Portales-Pérez D
    Transpl Immunol; 2009 May; 21(1):43-9. PubMed ID: 19233271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
    Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
    Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity.
    Chang HR; Lee MH; Wen MC; Lian JD
    Transplant Proc; 2004 Nov; 36(9):2668-70. PubMed ID: 15621119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C; Lerut E; Naesens M; Kuypers DR
    Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
    Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.